News
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...
Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of ...
Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...
Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss drug Wegovy. The ...
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on the pharmaceutical space.
Novo Nordisk on Monday said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results